Cyclin D1 is often deregulated in cancer and is a biomarker of cancer phenotype and disease progression, see [1]. Cyclin D1 has been shown to regulate the expression of genes that are involved in DNA replication and the DNA damage checkpoint, and it has also been shown to interact with DNA damage response proteins, see [2], [3]. Cyclin D1 overexpression is associated with shorter patient survival in many cancers and has been shown to associate with increased metastasis, see [4], [5]. The ability of Cyclin D1 to activate the cyclin-dependent kinases CDK4 and CDK6 is an extensively documented mechanism for its oncogenic actions and could therefore be a possible therapeutic target in future medicine, see [1].
This APP can be used for quantifying the nuclear expression of Cyclin D1. The approach to calculating expression used here, was demonstrated to have a very high correlation to manual scoring in a study involving 300 patients (R2 = 0.85), (publication pending).